Potential effects of financial conflicts of interest of speakers at the Pulmonary/Allergy Drug Advisory meetings by Bickford, Trevor et al.
The Potential effects of financial conflicts of interest of speakers at the 
Pulmonary/Allergy Drug Advisory meetings
Oklahoma State University Center for Health Sciences
Trevor Bickford, Nicholas Kinder, Wade Arthur, Cole Wayant, Matt Vassar PhD.
INTRODUCTION
The Pulmonary-Allergy Drugs Advisory 
Committee (PADAC) evaluates the safety and 
efficacy of new drugs used in the treatment of 
pulmonary, allergic, and immunologic diseases. 
Previous studies have shown positive 
recommendations from advisory committees 
are associated with drug approval by the FDA. 
We investigated the relationship between FCOI 
among public speakers and their 
recommendations for the drug under review as 
well as PADAC voting patterns.
OBJECTIVES
The primary objective of this study was to
investigate the relationship between FCOI 
among public speakers and their
recommendations for the drug under review at 
PADAC meetings. Our secondary
objective was to determine whether the 
number of speakers and the number of
speakers with FCOI were related to PADAC 
voting patterns.
METHODS
We included the testimonies of all public We 
included the testimonies of all public speakers 
at the PADAC meetings from November 2009 
to May 2019 using verbatim transcripts 
deposited on the FDA website. We used a pilot 
tested Google form to perform blinded, 
independent data extraction for each speaker. 
An ordered logistic regression was performed 
with each speaker's overall statement about 
the drug — negative, positive or neutral —
serving as the dependent variable. 
Independent variables included whether the 
speaker was taking the drug in question, 
whether the speaker had the disorder treated 
by the drug, and whether the speaker disclosed 
a FCOI. Stata 15.1 was used for all analyses.
Our findings suggest that public speakers who 
have FCOI are more likely to
recommend drugs for approval, at least within 
the context of PADAC. However,
these findings combined with others show a 
consistent effect. Greater efforts are
needed to understand the effects of public 
speakers on voting behaviors. Changes to the 
current guidance on FDA FCOI disclosure are 
needed, and the future role of
public speakers should be questioned.
Figure 1: Vote outcomes in relation to speaker number
Our ordered logistic regression model found that speakers who 
disclosed a FCOI were significantly more likely to give a positive 
testimony than those who did not (OR = 5.13, 95% CI = 1.83—
14.37, P < 0.001) and that speakers who had the disorder for 
which the drug was taken were significantly more likely to 
provide positive testimony than speakers who did not have the 
disorder (OR=5.49, 95% CI = 1.84 — 14.37, P < .01). Speakers 
who took the medication in question were not more likely to 
provide a positive testimony than those who did not (OR = 3.38, 
95% CI = 0.32—35.42, P = 0.31). The width of these confidence 
intervals, however, limits the certainty of these findings.
Figure 1 shows the voting results and the number of public 
speakers for each drug meeting. Nine (of 10) votes with five or 
less speakers had a vote swing of six or more. There were 3 vote 
swings of 3 or less; 2 of which had more than five speakers. One 
of them, which included more than five speakers with a vote 
swing of three or less, had 100% public speakers with FCOI; the 
other had 60%. A sub-analysis of the 2 Bronchitol meetings 
found a 122% increase in the number of public speakers and a 
300% increase in the number of speakers with a FCOI between 
the 2013 Bronchitol meeting and the 2019 meeting. Bronchitol
had 9 speakers in 2013 — 3 (33%) with FCOI — and the vote was 
0-14. In the 2019 Bronchitol session there were 20 speakers —
12 (60%) with FCOI — and the vote was 9-7.
Table 1: Number of speakers with FCOI 
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Total Speakers Speakers with FCOI
Drug Name Presented 
at Hearing
Drug Company # Speakers▴ # Speakers with 
Disclosed Financial 
Conflicts of Interest⬪
Bronchitol (2019) Chiesi 20 (15.63%) 12 (24.49%)
Long-acting beta-2 
agonist
Merck 4 (3.13%) 2 (4.08%)
Xolair Genentech and 
Novartis 
3 (2.34%) 2 (4.08%)
Umeclidinium/Vilanter
ol 
GlaxoSmithKline (GSK) 3 (2.34%) 1 (2.04%)
Tiotropium Bromide Boehringer Ingelheim 
Pharmaceuticals
2 (1.56%) 0 (0%)
Pirfenidone InterMune 18 (14.06%) 4 (8.16%)
Olodaterol Boehringer Ingelheim 
Pharmaceuticals
1 (0.78%) 0 (0%)
Bronchitol (2013) Pharmaxis 9 (7.03%) 3 (6.12%)
Mannitol Challenge Pharmaxis 8 (6.25%) 7 (14.29%)
Lumacaftor/Ivacaftor Vertex 20 (15.63%) 4 (8.16%)
Ivacaftor Vertex 10 (7.81%) 2 (4.08%)
Indacaterol Novartis 3 (2.34%) 1 (2.04%)
Icatibant Jerini US, Inc. 5 (3.91%) 5 (10.20%)
Fluticasone 
Furoate/Vilanterol 
(2013)
GlaxoSmithKline (GSK) 3(2.34%) 0 (0%)
Fluticasone 
Furoate/Vilanterol 
(2015)
GlaxoSmithKline (GSK) 2 (1.56%) 0 (0%)
Epinephrine inhalation 
OTC
Armstrong 
Pharmaceuticals, Inc.
7 (5.47%) 0
Ecallantide Dyax 6 (4.69%) 6 (12.24%)
Codeine N/A 3 (2.34%) 0 (0%)
Aclidinium bromide Forest Laboratories, Inc. 1 (0.78%) 0 (0%)
▴Percentage from total number of speakers (n=128)
⬪ Percentage from total number of speakers with financial conflicts of interest (n=49)
